DESTINY-Breast12
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
- NCT04739761 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DESTINY-Breast12 (trastuzumab deruxtecan in previously treated advanced/metastatic HER2-positive breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses DESTINY-Breast12’s nonrandomized evaluation of T-DXd in HER2-positive advanced breast cancer, including patients with active or stable brain metastases and a cohort without brain metastases. Discussion covers intracranial activity, the inclusion of patients with active brain disease, and how the findings may inform treatment sequencing and second-line use, including tucatinib. A speaker asks whether T-DXd is active in this population; commentary also raises whether its use is appropriate for all patients and discusses interstitial lung disease.
Indexed commentary on DESTINY-Breast12 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 72 | |
| Podcasts | 35 | |
| X threads | 32 | |
| X videos | 4 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Deruxtecan
- Arms
- Trastuzumab Deruxtecan · Experimental
- Enrollment
- 506
- Primary outcomes
- Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
- Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jun 22, 2021
- Primary completion
- Feb 8, 2024
- Results posted
- Yes
- Registry record
- NCT04739761 · updated Aug 11, 2026
Publications
linked from the registry- Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gion M, Guarneri V, Bianchini G, Wildiers H, Escriva-de-Romani S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. PubMed 39271844